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Abstract 
Upon activation, platelets release plasma-
membrane derived microparticles (PMPs) 
exposing phosphatidylserine (PS) on their 
surface. The function and clearance mechanism 
of these MPs are incompletely understood. As 
they are pro-coagulant and potentially pro-
inflammatory, rapid clearance from the 
circulation is essential for prevention of 
thrombotic diseases. The tyrosine kinase 
receptors Tyro3, Axl and Mer (TAMs) and their 
ligands protein S and Gas6 are involved in the 
uptake of PS-exposing apoptotic cells in 
macrophages and dendritic cells. Both TAMs 
and their ligands are expressed in the 
vasculature, the functional significance of which 
is poorly understood. In this study we 
investigated how vascular TAMs and their 
ligands may mediate endothelial uptake of 
PMPs. PMPs, generated from purified human 
platelets, were isolated by ultracentrifugation 
and labeled with biotin or PKH67. The uptake of 
labeled MPs in the presence of protein S and 
Gas6 in human aortic endothelial cells (HAEC) 
and human umbilical vein endothelial cells 
(HUVEC) was monitored by flow cytometry, 
western blotting and confocal/electron 
microscopy. We found that both endothelial cell 
types can phagocytose PMPs, and using TAM-
blocking antibodies or siRNA knock-down of 
individual TAMs we show that the uptake is 
mediated by endothelial Axl and Gas6. As 
circulating PMPs-levels were not altered in 
Gas6-/- mice compared to Gas6+/+ mice, we 
hypothesize that the Gas6-mediated uptake is not 
a means to clear the bulk of circulating PMPs 
but may serve to phagocytose PMPs locally 
generated at sites of platelet activation and as a 
way to affect endothelial responses. 
 
Introduction 
Platelets are key players in the regulation of 
haemostasis, coagulation and thrombosis. Upon 
activation, platelets shed small, 100 nm to 1 µm 
vesicles, often referred to as microparticles 
(PMPs), microvesicles or extracellular vesicles. 
These PMPs expose a hundredfold more 
phosphatidylserine (PS) on their surface than 
activated platelets themselves, and by supporting 
the activation of factor X and prothrombin they 
are highly pro-coagulant (1). However, the 
activated protein C system together with protein 
S has the ability to downregulate their pro-
coagulant phenotype, thereby creating a balance 
between coagulation and anti-coagulation (2). In 
addition to plasma membrane-derived PMPs, 
platelets also shed exosomes upon activation. 
These vesicles are usually derived from 
multivesicular bodies within the cell and carry 
different cargo and surface composition than 
PMPs. Furthermore, platelet exosomes are 
generally smaller than PMPs (3). However, 
using currently available methods, PMPs and 
platelet-derived exosomes are still difficult to 
analytically distinguish from one another.  
Furthermore, whether the pool of CD41-positive 
PMPs in the circulation is derived from platelets 
upon activation or directly from megakaryocytes 
is still unclear (4,5).  
Flow cytometric studies have shown that PMPs 
contribute to more than 70% of the circulating 
microparticle (MP) pool (6,7) but the number 
has recently been challenged by an electron 
microscopy study that suggested ca. 25% of the 
MPs to be PMPs (8). However, their abundance 
may be further increased during several disease 
states (9,10). PMPs have disease-causing 
abilities apart from triggering thrombosis, e.g. as 
demonstrated by Boilard et al., who showed that 
PMPs trigger inflammatory responses in 
synovial fibroblasts and contribute to the 
pathogenesis of inflammatory arthritis (11). In 
addition, PMPs induce a pro-inflammatory 
response in endothelium, by upregulating 
adhesion molecule expression and cytokine 
secretion (12,13), effects attributed to PMP-
derived arachidonic acid (12) and the chemokine 
RANTES (14). In contrast, PMPs induce 
immunosuppressive effects in macrophages and 
dendritic cells (15) and induce the differentiation 
of CD4+ into Foxp3 regulatory T-cells (16), 
which suggests they may also downregulate 
inflammation. 
Labeled PMPs injected into rabbits were found 
to be cleared in less than 10 min (17), whereas 
the half life of transfused PMPs in humans was 
estimated to be 5.8 h (4). Macrophages have 
been shown to ingest PMPs in a lactadherin-
dependent manner and splenectomized mice 
showed an increase in the amount of circulating 
PMPs, indicating that the spleen is an important 
site of clearance (18). Furthermore, β-2-
glycoprotein was shown to serve as an inducer 
of PMP phagocytosis by THP-1-derived 
macrophages (19). In addition, human umbilical 
vein endothelial cells (HUVECs) and brain 
endothelial cells have been shown to 
phagocytose PMPs, the former in a Del-1-
dependent manner (20-22). Activated 
neutrophils can also ingest PMPs, an uptake 
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triggered by 12(S)-hydroxyeicosatetranoic acid 
(12(S)-HETE) (23). This shows that there are 
several overlapping mechanisms of PMP-
removal from the circulation, which may 
promote different cellular outcomes in the 
recipient cells.  
Phagocytosis of PS-exposing apoptotic cells is 
mediated by several receptor-ligand systems, 
one of which is the TAM-receptor-Gas6/protein 
S system. The members of the TAM-receptor 
family, comprising Tyro3, Axl and Mer, are 
predominantly known for their ability to induce 
phagocytosis of apoptotic cells in macrophages 
and dendritic cells (24,25) as well as in Sertoli 
cells in the testis (26,27), retinal pigment 
epithelial cells (28) and microglia (29). 
Importantly, this inhibits inflammatory 
responses by modulating the activation of NF-
kB and inducing the expression of silencers of 
cytokine secretion (SOCS) 1 and 3 (30,31). The 
TAMs are activated by two main ligands, Gas6 
and protein S, each containing a gamma-
carboxylated GLA domain, which allows them 
to bind negatively charged phospholipids, such 
as PS, exposed among others on apoptotic cells 
and PMPs.  This interaction thus promotes an 
interaction between the TAM-expressing cell 
and the PS-exposing surface (32). 
Both Axl and Mer are expressed in endothelium, 
where they modulate angiogenesis (33-35) and 
induce cell survival (36,37). Moreover, 
endothelial Axl activation by Gas6 increases 
tissue factor expression, thus promoting 
thrombogenesis (38,39). Gas6 deficiency has 
accordingly been shown to protect mice against 
thrombosis, an effect, which in addition to 
endothelial modulation, may be due to a direct 
platelet-stimulatory effect of Gas6 (40). Further 
roles for endothelial TAM-receptors remain to 
be described.  
In this study we have investigated the 
involvement of endothelial TAM-receptors in 
the uptake on PS-exposing PMPs and the 
selectivity of the TAM-ligands for this uptake. 
We show that two different primary endothelial 
cell types efficiently phagocytose PMPs in an 
Axl-Gas6 dependent manner. This provides a 
novel role for endothelial TAM-receptors and 
strengthens the role of Axl as a phagocytic 
receptor.    
 
Materials and methods 
Cell culture 
Human umbilical vein endothelial cells 
(HUVEC, Life Technologies) and human aortic 
endothelial cells (HAEC, Life Technologies) 
were cultured on gelatin-coated flasks/plates in 
M200 medium supplemented with low serum 
growth supplement (Life Technologies) as well 
as 50 U/ml penicillin and 50 µg/ml 
streptomycin. THP-1 cells were cultured in 
RPMI 1640 supplemented with 10 % fetal calf 
serum (FCS), 2 mM L-glutamine, 50 U/ml 
penicillin and 50 µg/ml streptomycin. All cells 
were cultured in a humidified chamber with 5% 
CO2 at +37°C. 
 
Proteins 
Rabbit anti-Protein S (A0384, Dako) and rabbit 
anti-Gas6 (0005, homemade) were labeled with 
Alexa Fluor 488 using the microscale Protein 
Labeling kit (A30006) from Life Technologies. 
Soluble Axl (sAxl) comprising the extracellular 
domain alone was expressed and purified as 
described elsewhere (41). Human α-
thrombin was prepared from prothrombin as 
described in (42).  
 
Purification of Gas6 
Recombinant human Gas6 was expressed in 
Hek293 cells in the presence of 10 µg/ml 
vitamin K and purified as described previously 
(43) with the following modifications. 
Expression media with recombinant human 
Gas6 was supplemented with 1mM PMSF and 
50 µg/ml soybean trypsin inhibitor, centrifuged 
at 2500 rpm for 10 minutes at 4°C and filtered 
through a 0.45 µm membrane. A DEAE 
Sephacel matrix (150 ml, GE Healthcare) 
equilibrated with 20 mM Tris-HCl pH 8.0, 50 
mM NaCl was added and incubated with the cell 
medium for 2h at +4°C with stirring. The 
unbound fraction was collected and diluted 1:2 
with filtered distilled water. A fresh DEAE 
Sephacel resin equilibrated in 20 mM Tris-HCl 
pH 8.0, 20 mM NaCl was added and incubation 
was continued for 2h at +4°C. The resin was 
packed into a column and washed with 20 mM 
Tris-HCl pH 8.0, 20 mM NaCl. Bound proteins 
were eluted with a 20-500 mM NaCl gradient in 
20 mM Tris-HCl, pH 8.0. Gas6-containing 
fractions were collected, pooled and 
concentrated on 10 kDa MWCO spin columns 
(Amicon). The concentrated sample was 
separated on a Superdex 200 column (GE 
Healthcare), and eluted with 100 mM NaCl in 20 
mM Tris-HCl, pH 8.0. Gas6-containing fractions 
were pooled and stored in aliquots at -70°C after 
verification of protein purity.  
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Purification of protein S 
Protein S was purified from fresh-frozen human 
plasma according to a previously published 
method (44) with the following changes: The 
BaCl2-precipitate was dissolved in 0.2 M EDTA 
containing 10 mM benzamidine and 0.1 mM 
PMSF, after which ammoniumsulfate was added 
stepwise to 40% saturation. The mixture was 
stirred o/n at +4C and then  centrifuged at 2400 
g for 20 min at +4°C to remove precipitated 
proteins. Ammoniumsulfate was added to the 
supernatant to a final concentration of 67% and 
the sample was stirred at +4°C for 1 h to induce 
precipitation of vitamin-K dependent proteins. 
The precipitate was collected by centrifugation 
at 15 000g for 20 min at +4°C after which it was 
dissolved in 0.1 M sodium phosphate pH 6.0, 10 
mM benzamidine, 0.1 mM PMSF, 1% Tween-
20. The sample was dialyzed o/n against 0.1 M 
sodium phosphate pH 6.0, 10 mM benzamidine, 
0.1 mM PMSF with three buffer changes. After 
filtering through a 0.45 µm filter, the sample 
was applied to a DEAE Sephacel matrix (GE 
Healthcare) equilibrated with 0.1 M sodium 
phosphate pH 6.0, 10 mM benzamidine, 0.1 mM 
PMSF. The column was washed with 0.1 M 
sodium phosphate pH 6.0, 10 mM benzamidine, 
0.1 mM PMSF, 1% Tween-20 and 0.1 M sodium 
phosphate pH 6.0, 100 mM NaCl, 10 mM 
benzamidine, 0.1 mM PMSF. Bound proteins 
were then eluted with a linear gradient of 100-
700 mM NaCl in 0.1 M sodium phosphate pH 
6.0, 10 mM benzamidine, 0.1 mM PMSF after 
which free protein S-containing fractions were 
pooled. The sample was dialyzed against 20 mM 
Tris-HCl pH 7.5, 100 mM NaCl, 10 mM 
benzamidine, 0.1 mM PMSF and passed through 
a Blue Sepharose column (GE Healthcare) 
equilibrated with 20 mM Tris-HCl pH 7.5, 1 
mM EDTA, 100 mM NaCl, 10 mM 
benzamidine, 0.1 mM PMSF. The unbound 
fraction containing protein S was collected and 
passed through a 5 ml HiTrap column (GE 
Healthcare) coupled with an in-house 
monoclonal antibody against C4BP (MK104) to 
ensure complete removal of C4BP-bound 
protein S. The flow through was further purified 
on a HiTrap-column coupled with an in-house 
monoclonal antibody against protein S (MK21) 
(45). The pure protein S was dialyzed against 
TBS containing 2 mM CaCl2 and stored in 
aliquots at -80°C. 
 
 
Purification of sMer 
cDNA comprising aa 1-490 of the Mer 
extracellular domain was cloned into a 
pcDNA3.1 vector with a  thrombin cleavage site 
and a 6xHis sequence in the 3’ end (41). The 
vector was transfected into Hek293 cells and 
stably expressing clones were selected using 
hygromycine selection medium. Conditioned 
medium was passed through a Ni2+-chelated 
HisTrap Excel column (GE Healthcare) using an 
Äkta Avant system. The column wash washed 
with TBS (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl) followed by 50 mM Tris-HCl pH 8.0, 
1000 mM NaCl and bound proteins were eluted 
using an imidazole gradient. sMer-containing 
fractions were pooled and dialyzed against TBS 
after which the 6xHis epitope was removed by 
adding thrombin to 3 mg/ml and incubating the 
sample for 2 h at +37°C. The sample was passed 
through the HisTrap excel column again and the 
flow through was collected. Thrombin was 
removed by passing the sample through a 
benzamidine column (GE Lifesciences). The 
sMer-containing pool was aliquoted and stored 
at -80°C. 
A commercially available Gas6, which was 
shown to lack proper gamma-carboxylation 
(885-GS) was from R&D Systems (46). 
 
 
Platelet microparticle preparation and 
labeling 
Platelets were purified from pooled, fresh human 
citrated blood collected from healthy volunteers 
as described (2) with the permission of the local 
ethical board at Lund University. MP formation 
was induced by stimulating platelets at a 
concentration of 100x106/ml with 5.9 µM 
calcium ionophore (A23187, Life Technologies) 
or 0.5 U/ml thrombin and 25 µg/ml collagen 
(Chrono-Log Corp.) in activation buffer 
(140 mM NaCl, 2.5 mM KCl, 0.1 mM MgCl2, 3 
mM CaCl2, 60 mM Hepes 0.5 mM NaH2PO4, 
5.5 mM glucose and 10 mM HCO3, pH 7.4), for 
25 min at +37°C. Intact platelets were removed 
by centrifugation at 1500g for 10 min at +4°C, 
and PMPs were collected by centrifuging the 
supernatant at 100 000g for 30 min at +4°C. The 
pelleted PMPs were either re-suspended in 5 
mg/ml BSA in PBS and frozen in aliquots at -
80°C or fluorescently labeled using the PKH67 
green fluorescent labeling kit (Sigma). 
Alternatively, PMPs were biotinylated by adding 
EZ-link Sulfo-NHS-LC-Biotin (Thermo 
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Scientific) during the ionophore stimulation. 
Excess non-reacted reagent was adsorbed by 
adding glycine to 100 mM, after which intact 
thrombocytes were removed as above and the 
PMPs were centrifuged at 100 000g for 30 min 
at +4°C. PMPs were labeled with anti-CD41a 
PerCP-Cy5.5 (340931, BD Biosciences) for 
counting by flow cytometry using an FC500 
flow cytometer (Beckman Coulter). Count 
Bright absolute counting beads (C36950, Life 
Technologies) were used as reference. Flow 
cytometry data analysis was carried out using 
the FlowJo 8.8.7 software (Tree Star Inc). PS-
exposure was verified by staining the PMPs with 
FITC-conjugated lactadherin (Haematologic 
Technologies Inc.) and biotinylation efficiency 
was evaluated by staining the PMPs with 
streptavidin-AF488 (Life Technologies). 
Alternatively, unlabeled and biotinylated PMPs 
were lysed in RIPA-buffer (50 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.1% SDS, 1% Triton X-
100, 0.5% deoxycholate supplemented with 
HALT protease & phosphatase inhibitor cocktail 
(Life Technologies)) and analyzed with SDS-
PAGE followed by western blotting under 
reducing conditions. Blots were then probed for 
biotin using the Vectastain ABC kit (Vectorlabs) 
to identify biotinylated proteins. Western blots 
were developed using an Immobilon Western 
Chemiluminescent HRP substrate (Millipore) 
and imaged in the BioRad ChemiDoc MP 
System and analyzed in the BioRad ImageLab 
software. The size distribution of PMPs was 
evaluated using nanotracking analysis 
(NanoSight).  
 
Preparation of erythrocyte and THP1-derived 
MPs 
Erythrocytes were purified from citrated blood 
by centrifugation at 250g for 15 min at RT. The 
plasma layer and buffy coat were removed and 
erythrocytes were pooled.  The erythrocytes 
were washed three times in activation buffer, 
and pelleted at 2500g for 10 min. Erythrocyte 
MP (eryMP) formation was induced using the 
calcium ionophore A23187 and subsequent 
PKH67-labeling was carried out as described for 
the PMPs, alternatively the particles were left 
unlabeled. 
THP-1 cells were seeded at a concentration of 
1x106 cells/ml in fresh-filtered (0.2 µm) RPMI 
1640 supplemented with 10% FCS and 20 µg/ml 
LPS (O111:B4, Sigma) and incubated at +37°C 
for 24 h. Intact cells were removed by 
centrifugation at 500g for 10 min followed by 
two centrifugations at 1500g for 10 min at RT. 
The supernatant was then ultracentrifuged at 
100.000g to collect THP-1 MPs and labeled with 
PKH67 as for the PMPs. 
 
Measuring PMPs in mouse plasma 
Gas6+/+ and Gas6-/- mice were progeny of the 
original colony (described in (40)), with a 
genetic mixed background of 50% 129/Sv x 
50% C57Bl6/J. Gas6-/- (n=13, 10 female, 3 male, 
mean age 13 weeks), and Gas6+/+ (n=10, 6 male, 
4 female, mean age 10 weeks) mice were 
anesthetized by i.p. injection of sodium 
pentobarbital (50 mg/mL, 150 mg/kg), after 
which blood was collected in acid citrate 
dextrose from the inferior vena cava. The blood 
was centrifuged at 750 rpm for 10 min (Thermo 
ALC PK13R centrifuge with rotor T516) and the 
platelet-rich plasma was collected. Platelets were 
removed by centrifugation at 2500g for 10 min 
at RT and platelet removal was verified by flow 
cytometry. The remaining platelet-poor plasma 
(PPP) was stained with bovine lactadherin-FITC 
(Haematologic Technologies Inc.) and rat anti-
mouse CD41-PE (BD Biosciences). Samples 
were analyzed on a Beckman Coulter Gallios 
flow cytometer calibrated with Megamix-Plus 
FSC beads (BioCytex) and a Nano Size Standard  
(Spherotech) to monitor events in the range of 
0.1-0.8 µm. This was shown to exclude events of 
intact platelets. Particles in this size range 
positive for CD41 were considered to be PMPs. 
To exclude that the signal was disturbed by 
aggregates of antibodies or lactadherin, PPP was 
treated with 0.2% Triton-X 100 during staining, 
which completely removed all PMP signal 
observed in the flow cytometer. Quantification 
of PMPs in the samples was performed by 
adding a known amount of calibration beads 
(Sperotech) to each sample. The Swiss Federal 
Veterinary Office approved the experiments. 
 
Phospholipid vesicle preparation 
Phospholipids (phosphatidylserine (PS), 
phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC), all from Avanti Polar 
Lipids) were dissolved in 10/90 (v/v) 
methanol/chloroform solution. Mixtures of the 
lipids (20%/20%/60% PS/PE/PC or 20%/80% 
PE/PC) (weight-based) were prepared in 10/90 
methanol/chloroform and stored at -20°C. 
Aliquots from the stocks were dried under N2, 
and then re-suspended in Tris-buffered saline 
(50 mM Tris-HCl, 150 mM NaCl, pH 8.0, TBS) 
at RT. Phospholipid vesicles were prepared by 
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subjecting phospholipid mixtures to freeze-thaw 
cycles combined with extrusion using the 
LiposoFast basic extruder (Armatis, Germany) 
as described in (47) using a membrane with a 
pore size of 100 nm. The phospholipid vesicles 
were used within 2 days.  
TAM expression analysis using flow 
cytometry 
HAECs and HUVECs were grown to 90% 
confluency in 12-well cell culture plates. Cells 
were washed with PBS, detached using TrypLE 
Express and washed once in full medium 
followed by one wash in 1% BSA in TBS. Anti-
TAM antibodies (Axl; AF154 R&D Systems, 
Mer; ab52968 Abcam, Tyro3; AF859 R&D 
Systems) diluted 1:200 were pre-incubated with  
or without 10 µg/ml sTAMs in 50 µl 1% BSA in 
TBS for 20 min. Cells were re-suspended in the 
antibody mixtures and incubated on ice for 1h. 
After two washes with 1% BSA in TBS, donkey 
anti-goat DyLight488 (Abcam) or goat anti-
rabbit Alexa Fluor488 (Invitrogen) was added 
and incubation was continued for 1 h on ice in 
the dark. Cells were washed twice with 1% BSA 
in TBS, re-suspended in 1% BSA in TBS and 
and analyzed immediately by flow cytometry 
(CyFlow Space, Partec). For monitoring TAM 
expression on platelets, TAM antibodies (as 
above) were incubated with 50 000 washed 
platelets in 1% BSA in PBS for 20 min at RT. 
Donkey anti-goat DyLight488 (Abcam) or goat 
anti-rabbit Alexa Fluor488 (Invitrogen) was 
added together with 3 µl anti-CD41a PerCP-
Cy5.5 and incubation was continued for 20 min 
in the dark at RT. The samples were then diluted 
to 500 µl in 1% BSA in TBS and analyzed 
immediately on a FC500 flow cytometer 
(Beckman Coulter). The particles were gated for 
based on CD41a positivity. 
 
 
Cell surface biotinylation for TAM analysis 
HAECs and HUVECs were grown to ca 90% 
confluency in full medium. The plates were 
placed on ice and rinsed three times with ice-
cold PBS. Sulfo-NHS-LC biotin was diluted to a 
concentration of 1 mM in PBS and incubated 
with the cells for 15 min on ice. Cells were 
washed three times with 100 mM glycine in PBS 
and lysed in RIPA buffer after which cell 
residues were removed by centrifugation at 
10000g for 1 min at +4°C. Axl and Mer were 
immunoprecipitated from Protein G-sepharose 
pre-cleared lysates corresponding to 100 µg total 
protein with anti-Axl AF154 and anti-Mer 
MAB8912 (both from R&D Systems). 
Immunoprecipitated proteins were subjected to 
SDS-PAGE and western blotting, and the 
membranes were probed for biotinylated 
proteins using the Vectastain ABC kit as above. 
The efficiency of the immunoprecipitation was 
evaluated by comparing Axl and Mer in lysates 
before and after immunoprecipitation, 
conforming that more than 97% of total Axl and 
Mer were indeed extracted.  
 
Binding of protein S and Gas6 to PMPs 
PMPs (50 000/sample) were incubated with 
increasing amounts of protein S, Gas6 or a 
combination of both in 1% BSA in TBS 
supplemented with 2 mM CaCl2 in a final 
volume of 50 µl. In some cases, samples were 
supplemented with annexin V (555416, BD 
Biosciences). To study the effect of calcium on 
the interaction, EDTA was added to 5 mM 
instead of CaCl2. After 20 min of incubation at 
RT, AF488-conjugated rabbit anti-protein S or 
rabbit anti-Gas6 was added to a concentration of 
0.6 µg/ml together with 3 µl anti-CD41a-
PerCPcy5.5 and incubation was continued for 20 
min at RT in the dark. Samples were diluted to 
500 µl in staining buffer and analyzed 
immediately on a FC500 flow cytometer. PMPs 
were gated on based on CD41a-staining. 
In order to evaluate the phospholipid-
dependence of the PMP-Gas6 interaction, PMPs 
were treated with 20 nM phospholipase A2 in 
TBS+2 mM CaCl2 for 15 min at +37°C. Gas6 at 
increasing concentrations was then added and 
binding was monitored as above. 
 
MP uptake using western blot 
HUVECs were starved for 1h in serum–free 
medium in a 12-well cell culture plate. 
Biotinylated PMPs (400 000/sample) were pre-
incubated with increasing concentrations of 
Gas6 in serum-free medium for 20 min at RT 
after which they were added to the cells. After 
1h incubation at +37°C, the cells were washed 
with PBS and incubated with Trypsin-EDTA for 
5 min at +37°C. Cells were detached by 
pipetting, transferred to tubes and washed twice 
with PBS, followed by lysis in RIPA-buffer 
containing HALT protease and phosphatase 
inhibitor cocktail and 2 mM Na-orthovanadate. 
Protein concentrations were measured using the 
Pierce BCA assay (23227). Per sample, 10 µg of 
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cell lysate was subjected to SDS-PAGE and 
western blot under reducing conditions, followed 
by probing the membranes for biotinylated 
proteins using the Vectastain ABC kit as 
described above. Beta-actin was detected as a 
loading control. Band intensities were quantified 
in the ImageLab software (BioRad) and signals 
of biotin were normalized to the beta-actin 
loading control.  
 
 
MP uptake using flow cytometry 
Gas6 at increasing concentrations was incubated 
with 800 000 PKH67-conjugated PMPs/THP-1 
MPs or 100 000 eryMPs in 500 µl serum-free 
medium for 20 min at RT after which the 
mixtures were added to cells pre-starved (1h) in 
serum-free medium. After 1h of incubation at 
+37°C, cells were washed with PBS, incubated 
with Trypsin-EDTA for 5 min at +37°C, 
followed by two additional washes with PBS. 
Cells were re-suspended in PBS and analyzed 
immediately using flow cytometry (CyFlow 
Space, Partec). In experiments involving TAM 
knock-down using siRNA, cells were transfected 
with siRNA 48h prior to uptake experiments and 
proper knock-down was analyzed by western 
blot in non-trypsinized cells transfected in 
parallel. To analyze the inhibitory effect of 
TAM-blocking antibodies, cells were pre-
starved 30 min in serum free medium after 
which anti-TAMs were added to a final 
concentration of 5 µg/ml and starvation was 
continued for an additional 30 min. PMPs were 
pre-incubated with a mixture of 0.25 µg/ml Gas6 
and 5 µg/ml anti-TAMs prior to incubation with 
cells as above.  To study the calcium-
dependency of the uptake, EDTA was added to 
the Gas6-MP mixtures to a concentration of 2.5 
mM. When evaluating the requirement of Axl-
kinase activity, HAECs were pre-treated for 15 
min with 0.5 µM R428 in starvation medium 
before adding PMP-Gas6-mixtures, which also 
were supplemented with R428. To analyze the 
dependency of actin and microtubule network 
remodeling for the uptake, HAECs were pre-
starved for 1h in serum-free medium in the 
presence of 0.3 µg/ml cytochalasin D (C2618, 
Sigma) or 0.3 µg/ml nocodazole (M1404, 
Sigma) prior to incubation with MP-Gas6-
mixtures also containing either reagent. 
 
MP uptake using electron microscopy 
To study PMP internalization with electron 
microscopy, HAECs were grown to 90% 
confluency in 6-well plates. The cells were 
washed with PBS and starved in serum-free 
medium for 1h. Biotinylated PMPs (800 000) 
were pre-incubated with 250 ng/ml Gas6 in 
starvation medium for 20 min after which they 
were incubated with the cells for 2h or 6h at 
+37°C. Cells were rinsed twice with PBS and 
fixed using 2.5% glutaraldehyde in 0.15 M 
sodium cacodylate buffer, pH 7.9. Specimens 
were then embedded in Epon 812 and 
ultrasectioned. For immunostaining, the sections 
were incubated with gold-conjugated 
streptavidin. Specimens were then examined at 
the Core Facility for Integrated Microscopy 
(CFIM), Panum Institute, Copenhagen 
University, in a Philips/FEI CM100 BioTWIN 
transmission electron microscope. Images were 
recorded with a side-mounted Olympus Veleta 
camera. 
 
Confocal microscopy 
HAECs were grown on gelatin-coated coverslips 
in 12-well cell culture plates and starved for 1h 
in serum-free medium. Fluorescent PMPs (800 
000) were incubated with 250 ng/ml Gas6 for 20 
min at RT and added to the cells. After 4 h at 
+37oC, the cells were washed, fixed in 4% 
paraformaldehyde in PBS for 20 min, washed 
with PBS and blocked 15 min in 1% BSA in 
PBS.  The cover slips were incubated with an 
anti-CD31 antibody (ab119339, Abcam) diluted 
in 1% BSA in PBS for 1h at RT and, following 
three washing steps, with a goat anti-mouse-
Alexa Fluor633 antibody (Life Technologies) 
for 1h at RT in the dark. The coverslips were 
washed with PBS and water and mounted onto 
Superfrost Plus microscopy slides using the 
ProLong Diamond Antifade Mountant with 
DAPI (Life Technologies). The samples were 
visualized in a LSM 510 Meta confocal 
Microscope (Zeiss) using a 63x objective.  
Cells treated with cytochalasin D or nocodazole 
were stained for actin and β-tubulin in Triton X-
100 permeabilized cells using phalloidin-AF546 
(A22283, Invitrogen) and mouse anti-β-tubulin 
(T5293, Sigma) followed by goat anti-mouse 
Alexa Fluor 488 (A11001, Invitrogen). The 
staining and visualization was performed as 
above. 
 
Phosphorylation in HAEC by PMPs 
HAECs were grown to 90% confluence in 6-
well plates. Cells were rinsed with PBS and 
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starved for 2h in serum-free medium prior to 
stimulation. Gas6 (0, 100 or 200 ng/ml) was pre-
incubated with 2x106 PMPs in 500 µl serum-free 
medium for 20 min at RT, after which the mixes 
were added to the cells. Two wells were 
stimulated in parallel for each sample setup. 
After 15 min incubation at +37°C, the cells were 
placed on ice, rinsed with ice-cold PBS and 
lysed in 200 µl RIPA-buffer (with HALT-
protease&phosphatase inhibitor cocktail as well 
as 2 mM sodium orthovanadate). Debris was 
removed by centrifugation at 10 000g for 5 min 
at +4°C. Cell lysate corresponding to 150 µg 
total protein was adjusted to 500 µl in lysis 
buffer and pre-cleared for 30 min with 30 µl 
Protein G sepharose suspension (Invitrogen). 
The supernatant was collected and Axl was 
immunoprecipitated using 1 µg anti-Axl AF154 
(R&D Systems) together with 30 µl protein G 
sepharose suspension for 1.5 h at +4°C. The 
beads were pelleted at 1000g for 5 min at +4°C 
and washed once with lysis buffer. The beads 
were incubated in reducing Laemmeli sample 
buffer for 5 min at 95°C, after which the 
supernatants were subjected to SDS-PAGE and 
western blot, followed by probing membranes 
with anti-phosphotyrosine (pY99, Santa Cruz 
Biotechnology) and anti-Axl (H-124, Santa Cruz 
Biotechnology). Blots were developed and 
imaged as above. 
To analyze Akt and Erk phosphorylation, lysates 
from above corresponding to 5 µg total protein 
were subjected to western blot analysis and 
probed with antibodies against phosphorylated 
and non-phosphorylated Akt (Akt (pan)) and P-
Akt ((S437) D93 XP), both from Cell Signaling 
and Erk (p44/42 MAPK (Erk1/2)) from Cell 
Signaling and anti-Phospho Erk1/Erk2 from 
R&D Systems. The blots were further probed for 
beta-actin as a loading control.  
 
Adhesion molecule expression  
HAECs were grown to 90% confluence in 12-
well plates and washed with PBS. PMPs 
(2x106/sample) were incubated with 0 or 250 
ng/ml Gas6 in serum-free medium for 20 min at 
RT and added to the cells. The cells were 
incubated with the PMPs for 20 min after which 
they were detached using TrypLE Express (Life 
Technologies) and transferred to microtiter 
plates containing full medium. The cells were 
washed once in 1% BSA in PBS and re-
suspended in fluorescently labeled antibodies 
against VCAM (FAB5649A), ICAM (BBA20), 
E-selectin (BBA21) or tissue factor 
(FAB23391A) (all from R&D Systems), diluted 
1:50, and incubated for 1h on ice in the dark. 
The cells were pelleted and washed once with 
1% BSA in PBS, after which they were re-
suspended in 1.5 ml 1% BSA in PBS and 
analyzed using flow cytometry (CyFlow Space, 
Partec). 
 
Statistical analysis 
Data are presented as mean values with standard 
deviation (SD) of at least three separate 
experiments. In some cases the error bars are too 
small to be seen in the graphs. Differences 
between groups were analyzed using one-way 
ANOVA followed by Tukey’s multiple 
comparison test, unless stated otherwise. p-
values below 0.05 were considered statistically 
significant. 
 
Results 
PMPs bind Gas6 and protein S 
To generate a phenotypically homogenous 
population of PMPs, we stimulated isolated 
human platelets with a calcium ionophore and 
collected released PMPs by ultracentrifugation. 
As PMPs are collected in one centrifugation step 
after platelet removal, we do not distinguish 
between released exosomes and MPs in this 
study. Upon ionophore-stimulation of platelets, 
the cells obtained a rounded shape with 
abundant vesicles forming on and released off 
the surface (Fig. 1A). To estimate the size of our 
ionophore-induced PMPs, we analyzed them by 
nanotracking analysis (NTA), which 
demonstrated that the mean size of the particles 
was just below 200 nm (Fig. 1B), matching well 
the reported size of naturally occurring PMPs. A 
general feature of PMPs of different cellular 
origin is their exposure of PS on the outer 
membrane. Our PMPs readily exposed PS, as 
measured by lactadherin-binding (Fig. 1C), 
further confirming their resemblance to 
physiological PMPs. In addition to binding 
protein S as has been reported earlier (48), we 
found that PMPs interact with Gas6 in a 
concentration-dependent manner (Fig. 1D and 
E). As Protein S has been shown to interact via 
its GLA-domain with the exposed PS on the 
PMP, we evaluated whether this is the case also 
for Gas6. When PMPs were treated with 
phospholipase A2, an enzyme that hydrolyzes 
phospholipids into arachidonic acid and 
lysophospholipids, Gas6-binding was abolished, 
demonstrating that Gas6 interacts with 
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phospholipids on the PMP surface (Fig. 1F).  To 
confirm that the main ligand was PS, Gas6 was 
pre-incubated with phospholipid vesicles 
composed of either 80% PC and 20% PE or 
alternatively 60% PC, 20% PE and 20% PS 
before addition to the PMPs. Only PS-containing 
vesicles were able to block the interaction 
between Gas6 and the PMPs, indicating that PS 
is a binding site for Gas6 on the PMPs (Fig. 1G). 
In addition, a commercially available Gas6, 
which has previously been shown to lack proper 
gamma-carboxylation of the GLA-domain (46), 
did not bind PMPs (Fig. 1H). EDTA blocked the 
Gas6-PMP interaction completely, showing that 
the interaction is furthermore dependent on 
calcium, a general feature of GLA-dependent 
interactions with negatively charged 
phospholipids (Fig. 1I). Despite both protein S 
and Gas6 binding to the exposed PS on the PMP, 
they did not compete for the same binding site, 
as protein S could not inhibit the binding of 
Gas6 to PMPs even at high doses (Fig. 1J). 
Previous studies have shown that both protein S 
and Gas6 may bind simultaneously to apoptotic 
cells, and that neither protein S nor Gas6 binding 
to the apoptotic cell is disturbed by annexin V 
(49). Consistent with this observation, annexin V 
at 500-fold molar excess inhibited Gas6 from 
binding to PMPs only to an average of 26% and 
protein S from binding to PMPs to 44% (not 
shown). 
Earlier studies have reported conflicting results 
on whether human platelets themselves express 
TAMs. Gould et al. demonstrated using flow 
cytometry that human platelets contain all three 
TAMs (50), whereas Cosemans et al. showed 
that platelets contain intracellular Axl using 
immunoelectron microscopy (51). We were not, 
however, able to detect TAM-receptors on 
human platelets by flow cytometry (Fig. 1K) or 
western blot analysis (not shown) using our in-
house polyclonal antibodies or commercially 
available antibodies. A recent study utilizing 
mass spectrometry to describe the whole platelet 
proteome reported the presence of protein S but 
not Gas6 or TAM-receptors in platelets (52). In 
this study, proteins expressed at even less than 
500 copies per platelet were identified, 
indicating that if TAMs were present in platelets, 
they would indeed be expressed at a very low 
level. To rule out that Gas6 might bind to any 
Axl present on the platelet surface, we evaluated 
the ability of a soluble Axl (sAxl) construct 
comprising the extracellular domain alone to 
block the interaction between Gas6 and the 
PMPs. sAxl at a high molar overdose inhibited 
the binding of Gas6 to the PMPs only to approx. 
10%, demonstrating that PMP Axl is not an 
important binding site for Gas6 (Fig. 1L). This 
was further confirmed by the lack of interaction 
of the improperly gamma-carboxylated Gas6 
with the PMPs (Fig. 1H), as the binding of Gas6 
to TAMs has been shown to be normal in the 
absence of a functional GLA-domain (53). 
 
 
HUVECs and HAECs ingest PMPs in a Gas6-
Axl dependent manner 
HUVECs have previously been shown to 
express TAMs, and we confirmed the presence 
of cell surface Axl and Mer by flow cytometry, 
whereas no Tyro3 expression could be detected 
(Fig. 2A). To investigate their relative 
abundance, the cell surface was biotinylated, 
after which Axl and Mer were 
immunoprecipitated and analyzed by western 
blot for biotin (Fig. 2B). We found that Axl and 
Mer expression varied somewhat depending on 
the cell confluence and growth conditions, but 
generally their expression was in the same order 
of magnitude, i.e. none of the proteins was 
expressed more than 5-fold more abundantly 
than the other.  
To elucidate whether HUVECs could ingest 
PMPs, PKH67-labeled PMPs were first pre-
incubated with an increasing amount of Gas6, 
after which they were incubated with HUVECs 
for 1h. Flow cytometric analysis of the cells 
showed a dose-dependent uptake of Gas6-coated 
PMPs (Fig. 2C). The Gas6-mediated uptake was 
abolished by treating the cells with Axl-targeting 
antibodies, whereas antibodies against Mer or 
Tyro3 had no effect (Fig. 2D).  
To rule out any effect of the added fluorescent 
marker on the PMPs, a biotinylated preparation 
of PMPs was generated. Proper biotin labeling 
of the PMPs was verified both using flow 
cytometry (Fig. 2E) as well as western blotting 
(Fig. 2F), which showed that several surface 
proteins on the PMPs were biotinylated. The 
strongest band around 100kDa was used for 
quantification in uptake experiments. 
Biotinylated PMPs were incubated with 
HUVECs for 1h after which their uptake was 
monitored by western blot analysis of cell 
lysates. Only a very low uptake of PMPs by 
HUVECs was observed in the absence of Gas6, 
whereas Gas6 induced a strong, dose-dependent 
PMP ingestion (Fig. 2G). This uptake was 
evident already at Gas6-concentrations below 
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100 ng/ml, indicating that very low, 
physiologically relevant amounts of Gas6 are 
sufficient to induce PMP uptake.  
Incubating the cells with an excess of unlabeled 
PMPs during the uptake attenuated the uptake of 
fluorescent PMPs, confirming the specificity of 
the process (Fig. 2H). The uptake was 
furthermore inhibited in the presence of EDTA, 
which prevents Gas6 from binding to the PMP 
surface (Fig. 2I). These results show that 
HUVECs can ingest PMPs in an Axl-Gas6-
dependent manner. 
 
We further evaluated the ability of primary 
aortic endothelial cells (HAEC) to ingest PMPs 
to investigate whether other types of endothelial 
cells display similar properties. The expression 
pattern of TAMs on HAECs was found to be 
similar to that on HUVECs (Fig. 3A and B). 
Similarly to these cells, HAECs also ingested 
PMPs in a Gas6-dependent manner (Fig. 3C).  
Targeting cell-surface Axl with antibodies or 
silencing the Axl expression with siRNA 
abolished the uptake, as in HUVECs (Fig. 3D 
and E). Importantly, non-gamma-carboxylated 
Gas6 did not induce PMP phagocytosis even at 
higher concentrations (Fig. 3G). The amount of 
ingested particles increased dramatically as the 
incubation time was extended (Fig. 3H), mainly 
in a Gas6-dependent manner.  
 
Gas6 stimulates PMP uptake even in the 
presence of protein S 
As protein S is an abundant plasma protein and 
was found to readily bind PMPs, we evaluated 
its ability to induce PMP uptake. Surprisingly, 
physiological amounts of protein S did not 
increase PMP uptake in HUVECs (Fig. 4A) and 
actually inhibited the Gas6-independent uptake 
in HAECs (Fig. 4B). This shows that different 
endothelial cells have different basal PMP 
uptake mechanisms. Correspondingly, Gas6 
readily increased the PMP uptake in HUVECs 
even in the presence of 10 µg/ml protein S (Fig. 
4C). In HAECs, Gas6 gave a dose-dependent 
stimulation of uptake even in the presence of 
protein S. However, the total uptake signal was 
relatively low due to the protein S-dependent 
blockage of the basal uptake (Fig. 4D). When 
the uptake experiment was carried out on ice, 
thereby preventing active ingestion, and without 
the trypsinization that we used to detach cell 
surface-bound particles, hardly any binding of 
PMPs to the HAECs could be observed, even in 
the presence of Gas6 or protein S (not shown). 
This suggests that other mechanisms are 
responsible for the initial interaction of the PMP 
with the cell, whereas Gas6 mainly potentiates 
the actual ingestion process. 
Consistent with the observation of annexin V 
only partially inhibiting the binding of Gas6 to 
the PMPs, annexin V inhibited Gas6-mediated 
PMP uptake in HUVEC to ca. 50% but did not 
interfere with the basal uptake (Fig. 4E). 
 
sAxl interferes with uptake depending on the cell 
type 
Circulating Gas6 has been shown to be in 
complex with soluble Axl (41), which might be 
a result of proteolytic Axl-release from the cell-
surface upon activation by Gas6 (53). The 
amount of free Gas6 seems to be the limiting 
factor determining the amount of formed 
complexes, as there is a molar excess of soluble 
Axl in plasma as compared to Gas6 (41). 
However, cells of the vasculature have been 
shown to produce Gas6 (54), which might result 
in free Gas6 molecules locally around the 
vascular wall. Soluble Axl is found in the 
circulation in healthy humans at concentrations 
ranging from 14 to 105 ng/ml, with a mean 
concentration of 42 ng/ml (41). Interestingly, 
soluble Axl at concentrations up to 500 ng/ml 
caused only a slight decrease in the Gas6-
dependent PMP uptake in HAECs, whereas in 
HUVECs sAxl had a more pronounced 
inhibitory effect (Fig. 4F and G) showing that 
the presence of physiological sAxl 
concentrations do not prevent PMP ingestion. 
 
 
The PMPs are actively internalized and localize 
around nuclei 
Using confocal microscopy, we could see that 
the ingested, Gas6-coated PMPs were properly 
internalized in the HAECs as opposed to merely 
bound to the cell surface and they accumulated 
around the nucleus (Fig. 5A).  
To further investigate the internalization process, 
we studied the uptake of biotinylated PMPs in 
HAEC cells by transmission electron 
microscopy where PMPs were visualized using 
an avidin-gold conjugate (Fig. 5B). PMPs of 
different sizes were found inside the cells both 
freely in the cytoplasm as well as in structures 
resembling endosomal vesicles. Whether these 
were vesicles taken up by two distinct pathways 
or merely showed the same process at different 
timepoints remains to be elucidated.  
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The Gas6-dependent PMP phagocytosis in 
HAECs was an active process, as inhibition of 
cytoskeletal rearrangement with cytochalasin D 
or nocodazole prevented PMP-uptake (Fig. 5C). 
At the used concentrations, neither cytochalasin 
D nor nocodazole induced endothelial exposure 
of the apoptosis marker PS, as measured by 
annexin-V-staining. Furthermore, the binding of 
Gas6 to the PMPs was not inhibited in the 
presence of either chemical (not shown).  
 
PMP-bound Gas6 phosphorylates Axl 
Axl activation depends on phosphorylation of its 
intracellular kinase domain. Gas6 on its own is 
able to trigger Axl phosphorylation, but recent 
studies have suggested that the presence of PS-
exposing membranes increases the potential of 
Gas6 to phosphorylate Axl (53). We found that 
PMPs on their own did not phosphorylate Axl, 
but binding of Gas6 to the PMPs potentiated the 
ability of Gas6 to activate Axl (Fig. 6A). Axl 
activation by Gas6 has been shown to induce 
down-stream activation or Akt and Erk1/2 MAP 
kinases in several cell-lines. Gas6 stimulation of 
HAECs induced Akt-phosphorylation, which 
was further increased by the presence of PMPs 
(Fig. 6B). However, PMPs on their own also 
induced a certain amount of Akt-
phosphorylation in HAECs. The PMPs also 
induced a low amount of Erk1/2-
phosphorylation (Fig. 6C), whereas Gas6 had no 
effect on Erk1/2-activation in these cells. This 
shows that PMP-bound Gas6 may induce 
differential Axl-signaling in endothelium 
compared to circulating Gas6 or at least affect 
the intensity of the stimulation. Addition of an 
Axl kinase inhibitor (R428) prevented Gas6-
dependent uptake of fluorescent PMPs in 
HAECs, confirming that the observed Axl 
phosphorylation is necessary to trigger ingestion 
(Fig. 6D). 
 
Thrombin/collagen-generated PMPs are 
ingested similarly to ionophore-generated PMPs 
PMPs generated by ionophore-stimulation may 
have a different phenotype from physiological 
PMPs generated in the circulation, and 
differences in the size and proteome of formed 
PMPs have been described when platelets were 
stimulated with an ionophore or a combination 
of thrombin and collagen (3). To elucidate 
whether the uptake we observe is dependent on 
the mechanism by which we induce PMP-
formation, we stimulated purified human 
platelets with a combination of thrombin and 
collagen and isolated and labeled released PMPs 
(TC-PMPs) with the same techniques that were 
used for the ionophore PMPs. When analyzed by 
electron microscopy, the thrombin and collagen-
stimulated platelets showed signs of typical 
platelet activation with pseudopod formation and 
aggregation, in contrast to the ionophore-
activated platelets  (Fig. 7A). The size of the 
TC-PMPs was more heterogenous than that of 
the ionophore PMPs, as evaluated by NTA (Fig. 
7B). They also exposed slightly lower levels of 
PS than ionophore-induced PMPs (Fig. 7C), 
which was further reflected in a lower protein S- 
and Gas6–binding (Fig. 7D and E). 
Nevertheless, TC-PMPs were readily 
phagocytosed by HAECs in a Gas6-dependent 
manner, whereas protein S, as expected, did not 
stimulate uptake (Fig. 7F).  This shows that also 
PMPs generated in a more physiological manner 
are taken up in primary human endothelium in a 
Gas6-dependent way.  
 
Erythrocyte MPs and THP-1 MPs are less 
dependent on Gas6 for uptake in HAEC 
We further wanted to study whether MPs 
derived from other host cells could be taken up 
in HAECs via Gas6 and TAMs. Aged 
erythrocytes have been shown to be ingested in 
angiogenic HUVECs in a manner dependent on 
lactadherin (55), and erythrocyte-derived 
microparticles (eryMPs) are known to bind 
protein S (56). We therefore evaluated whether 
Gas6 could interact with eryMPs and induce 
their uptake in HAECs. EryMPs were generated 
by stimulation of purified human erythrocytes 
with a calcium ionophore and isolated by 
ultracentrifugation as the PMPs. They exposed 
PS on their surface as shown by their ability to 
bind lactadherin (Fig. 7G) and protein S (Fig. 
7H). In contrast, Gas6 showed only a very weak 
binding to isolated eryMPs (Fig. 7I). PKH67-
labeled eryMPs were readily phagocytosed by 
HAECs even in the absence of Gas6, but the 
uptake was significantly increased when Gas6 
was present (Fig. 7J). This shows that even 
minor amounts of Gas6 on the surface of the 
eryMP are sufficient to promote uptake. This 
may indicate that other proteins regulate the 
docking process of the eryMP to the cell surface, 
whereas Gas6 triggers the actual ingestion 
process. 
THP-1 MPs have also shown to be phagocytosed 
by endothelial cells (57). We therefore generated 
THP-1 MPs by LPS stimulation, which 
generated PS-positive particles (Fig. 7K) that in 
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addition had the ability to bind protein S and 
Gas6 (Fig. 7L and M). HAECs were able to 
phagocytose THP-1 MPs, an effect which was 
slightly, but not significantly, increased in the 
presence of Gas6 (Fig. 7N). Therefore, it seems 
that uptake mechanisms are slightly different 
both for MPs from different sources as well as in 
different endothelial cells.  
 
Inflammatory regulation by PMPs 
Several reports have shown that PMPs may have 
pro-inflammatory effects on the endothelium, 
among others by up-regulating the expression of 
adhesion molecules such as intercellular 
adhesion molecule (ICAM) (12,13) as well as 
cytokine secretion. When incubating HAECs for 
20h with PMPs, we saw a slight but significant 
increase in ICAM-expression, and this was 
further increased in the presence of PMP-bound 
Gas6 (Fig. 8). PMPs also induced the expression 
of E-selectin, again a feature, which was 
augmented in the presence of Gas6 (Fig. 8). 
However, only negligible amounts of VCAM 
and tissue factor were expressed on the HAECs 
after 20h MP stimulation. This confirms that 
PMPs do have a weakly pro-inflammatory 
phenotype, which seems to be increased when 
their uptake is promoted. 
 
Circulating PMPs in Gas6-/- mice 
As Gas6 was shown to be an important mediator 
of PMP uptake in cultured human endothelium, 
we investigated whether the same was true in 
vivo in mice. We therefore compared the levels 
of circulating CD41-positive PMPs in PPP of 
Gas6-/- and Gas6+/+ mice. We found no 
significant differences in the amount of 
circulating CD41+PS+ PMPs under basal 
conditions in the mice (Gas6-/-, mean 4059 
PMP/µl; Gas6+/+, mean 4028 PMP/µl), nor in 
the amount of CD41 single-positive PMPs 
(Gas6-/-, mean 532 PMP/µl; Gas6+/+, mean 383 
PMP/µl) (Fig. 9A). No significant differences 
were observed either when all PS+ MPs, i.e. not 
only the CD41-positive events, were analyzed 
(Gas6-/-, mean 13417 MP/µl; Gas6+/+, mean 
11303 MP/µl), showing that in general the levels 
of circulating MPs of different origins were not 
altered in Gas6-/- mice (Fig. 9B). Circulating 
MP-levels were not affected by age, however, in 
both Gas6-/- and Gas6+/+ mice, levels of PMPs as 
well as MPs in general were higher in males 
than females.  
 
Discussion 
Platelet MPs, which represent a large portion of 
circulating MPs, expose high amounts of PS, are 
highly pro-coagulant and have been suggested to 
contribute to thrombotic events. Despite their 
possibly harmful properties, little is still known 
about both the physiologic function of PMPs and 
their mode of clearance. Here we show that 
PMPs are readily ingested in primary human 
endothelial cells in a Gas6- and Axl-dependent 
manner. This uptake mechanism was not 
restricted to PMPs as also eryMPs were ingested 
in a Gas6-dependent manner. Despite the high 
abundance of the Gas6-homologue protein S in 
circulation and the ability of protein S to interact 
with Mer and Tyro3, exclusively Gas6 together 
with Axl were able to mediate MP phagocytosis 
in endothelium. This was not due to a substantial 
overexpression of Axl compared to Mer in the 
cells, but most likely reflects the higher affinity 
that Gas6 displays for Axl than for Mer. 
However, it has been demonstrated that most of 
the circulating Gas6 is bound to soluble Axl, 
which could argue that circulating Gas6 is 
inactive (41). Interestingly, we observed only a 
weak inhibition of PMP uptake in HAECs when 
Gas6 was pre-incubated with sAxl, whereas the 
inhibition was stronger in HUVECs. It is 
possible that Axl is glycosylated differently in 
various cells or associated with different 
receptor complexes altering its affinity for Gas6. 
Axl expressed in HAEC may form a stronger 
complex with Gas6 than the recombinant sAxl, 
thus promoting uptake. The cellular source of 
circulating sAxl may therefore be crucial for its 
ability to interfere with Axl/Gas6-signaling in 
different tissues. Alternatively, sAxl-Gas6-PMP 
complexes can possibly be recognized by Axl on 
HAECs, thereby promoting the association of 
PMPs to the cell surface. In this case, other PS-
recognizing receptors could stimulate the actual 
ingestion process. Both endothelial cells and 
vascular smooth muscle cells produce and 
secrete Gas6 (54,58) thereby possibly increasing 
the Gas6-concentration locally at the vessel wall. 
Moreover, the interaction between Gas6 and PS-
exposing apoptotic cells has been shown to 
occur within seconds (49), which might also be 
the case for the Gas6-PMP interaction. This 
would allow locally produced, newly released 
free Gas6 to complex with PMPs and trigger 
their uptake. The contribution of endothelial 
Gas6 for PMP uptake in vivo is still, however, 
unclear.   
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Protein S was found to inhibit Gas6-independent 
PMP uptake in HAECs but not in HUVECs, and 
antibodies targeting the protein S GLA-domain 
abolished the inhibitory effect (not shown), 
which indicates that protein S needs to associate 
with PS on the PMP in order to exert its 
inhibitory effect. It is likely that protein S can 
compete out the binding of other MP-opsonizing 
PS-ligands that mediate PMP uptake specifically 
in HAECs but not HUVECs. We also 
demonstrated that despite both protein S and 
Gas6 binding to PS on the PMP, neither of the 
molecules competed with each other for the 
same binding site, and annexin V could only 
partially compete out Protein S and Gas6 from 
the PMP. This indicates that membrane 
microdomains, and not general PS-exposure, are 
important for the selective association of PS-
ligands. 
A previous study demonstrated Del-1-dependent 
PMP uptake by HUVECs already within 30 min 
of PMP-exposure and also showed the 
importance of Del-1 for PMP uptake in lung and 
liver endothelium in vivo in mice (20). As we 
observed that the basal uptake mechanism in the 
absence of Gas6 differs between different types 
of endothelium, it is possible that uptake 
mechanisms differ in different organs. PMPs 
ingested in a Del-1-dependent manner 
accumulated to one side in the cell periphery, 
whereas Gas6-Axl mediated uptake showed a 
clear transport of PMPs to the immediate 
vicinity of the nucleus. This suggests that the 
uptake processes engage different pathways and 
may direct the PMPs to different intracellular 
processing, alternatively the cellular location 
differs upon increasing the uptake time, as we in 
our study visualized the cells after 4h of uptake. 
Furthermore, Del-1 mediated phagocytosis was 
restricted to larger PMPs sedimented at 20 000g. 
In this study we did not differentiate between big 
and small PMPs or PMPs and platelet-derived 
exosomes, and it is possible that Gas6-mediated 
uptake is restricted to a subpopulation of 
released vesicles. Brain endothelial cells were 
also shown to phagocytose PMPs in an active 
process depending on calcium, which was 
increased in the presence of heat-inactivated 
serum. Brain endothelial cells have been shown 
to express Axl and Tyro3 as well as low 
amounts of Mer, which may interact with Gas6 
and protein S (59,60).  Any of these receptors 
may potentially be responsible for PMP uptake 
in brain endothelium.  
Axl-mediated phagocytosis has previously been 
described to occur mainly in dendritic cells 
(25,61), and specifically under pro-inflammatory 
conditions (62), whereas Mer in both circulating 
and tissue-resident macrophages was suggested 
to contribute to homeostatic apoptotic clearance 
under tolerogenic settings. As the PMPs 
represent a large part of circulating MPs even 
under basal conditions, their phagocytic uptake 
could be expected to occur in a constantly 
ongoing manner resembling homeostatic Mer-
dependent phagocytosis. As this process in 
endothelium was independent of Mer, TAM-
dependent phagocytic processes are likely to be 
differentially regulated in different tissues. 
Whether TAMs expressed on macrophages 
mediate uptake of PMPs is, however, still 
unknown. 
Interestingly, we did not observe any differences 
in the basal levels of circulating MPs or PMPs in 
Gas6-deficient mice. However, we cannot 
exclude that different pathological conditions 
known to increase the release of cellular 
microparticles, such as metastatic cancer, 
thromboembolism or severe inflammation, 
might induce elevated circulating MP-levels in 
Gas6-/- mice compared to Gas6+/+ mice. The 
uptake process may additionally be different in 
mice than in men, as all cellular experiments we 
carried out were performed with isolated human 
cells and proteins. Despite extensive literature 
describing Axl expression in human 
endothelium, only a few reports have been 
published on the presence of Axl in murine 
endothelium (63,64). However, several studies 
have demonstrated Gas6-mediated responses in 
murine endothelium. As the TAMs are the only 
known receptors for Gas6, it is therefore likely 
that members of this receptor family are 
expressed also in murine endothelium. 
Furthermore, it is likely that overlapping 
mechanisms for PMP removal exists, which will 
compensate for the loss of any single one of 
them. It is possible that Del-1 may mediate 
uptake of PMPs in endothelium in the absence of 
Gas6, alternatively endothelial uptake is 
replaced by phagocytosis in macrophages and 
neutrophils.  A change in uptake mechanism 
may in addition alter the biologic impact of 
released PMPs. Another explanation may be that 
endothelial uptake of PMPs is not the 
predominant mechanism to clear the bulk of 
released PMPs from the circulation, but serve a 
specific function in regulation of endothelial 
responses. Such a role has been shown among 
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others in the delivery of functional Ago2-miR-
223 complexes from PMPs to HUVECs, which 
thereby regulate endogenous gene expression in 
the endothelium (22). Thereby, eliminating Gas6 
would not alter the levels of circulating PMPs, 
as the vast majority of them would be taken up 
in other cells and tissues. Gas6-/- mice have been 
shown to have slightly altered platelet responses 
(40), and hence we cannot exclude the 
possibility that platelets from Gas6-/- mice 
display reduced abilities to form PMPs. This 
might contribute to the decreased 
thrombogenicity observed in the mice, both by 
altering directly the initiation of coagulation as 
well as decreasing endothelial responses. Under 
basal conditions there was no difference in the 
proportion of CD41+ PMPs in relation to the 
total MP population between Gas6-/- and Gas6+/+ 
mice (34% in Gas6-/- and 38% in Gas6+/+), 
however this should be further studied in detail 
upon a platelet activating stimuli. 
In conclusion, we now show that 1) Gas6 
interacts with platelet derived MPs and 2) 
endothelial Axl can function as a phagocytic 
receptor. Whether this ability is limited to the 
uptake of MPs or whether PS-exposing apoptotic 
bodies are similarly ingested remains to be 
answered.  However, this expands our 
knowledge on the function of both TAMs and 
their ligands in the vasculature and may provide 
valuable insights to how thrombocytes interact 
with the vessel wall. In this light it will be 
intriguing to unveil the faith of ingested 
particles, whether they are a means of 
transportation of genetic material into target 
cells or if they are transported further into 
underlying tissues.  	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Figure legends 
 
FIGURE 1. PMPs bind Gas6 and protein S. Scanning electron micrographs of unstimulated isolated 
human platelets and human platelets stimulated with a calcium ionophore to induce MP-formation. 
Scale bars represent 5 µM (left and middle panel) and 100 nm (right panel) (A). The MP size 
distribution was evaluated by nanotracking analysis and showed a mean size of just below 200 nm 
(B). PMPs were evaluated for phosphatidylserine-exposure by measuring their ability to bind 
fluorescent lactadherin using flow cytometry (C). PMPs were incubated with increasing amounts of 
Gas6 and protein S before fluorescent antibodies were added. Binding was monitored by flow 
cytometry (D and E). PMPs were treated with or without phospholipase A2 (PLA2) before Gas6-
binding was evaluated by flow cytometry (F). Gas6 was pre-incubated with liposomes composed of 
PS, PE and PC or PE and PC alone before incubation with PMPs. Gas6 binding was evaluated with 
flow cytometry (G). PMPs were incubated with gamma-carboxylated (own Gas6) and non-gamma-
carboxylated Gas6 (RnD Gas6) and the amount of bound protein was evaluated with an antibody 
recognizing both Gas6-variants using flow cytometry (H). Gas6 was incubated with PMPs in the 
presence or absence of 5 mM EDTA to measure the calcium-specificity of the Gas6-MP interaction 
(I). PMPs were incubated with 250 ng/ml Gas6 in the presence of increasing amounts of protein S 
after which fluorescent Gas6-recognizing antibodies were added. The amount of PMP-associated 
Gas6 was evaluated using flow cytometry (J). The expression of TAMs on the surface of the PMPs 
was evaluated using flow cytometry (K). sAxl at increasing concentrations was pre-incubated with 
Gas6 before adding PMPs, and the amount of MP-bound Gas6 was evaluated using flow cytometry 
(L). Data in D-J and L are shown as mean and SD of three individual experiments. Panels C and K 
shown representative histograms from at least three individual experiments. ns, not significant; **, 
p<0.01; ***, p<0.001; ****, p<0.0001.   
 
FIGURE 2. HUVECs ingest PMPs in a Gas6-Axl dependent manner. TAM-expression on the surface 
of HUVECs was evaluated using flow cytometry. Antibody specificity was verified by pre-incubating 
the anti-TAMs with soluble TAMs prior to addition of cells (A). The relative expression of Axl and 
Mer on the plasma membrane was measured by western blotting after immunoprecipitation of Axl 
and Mer from cell-surface biotinylated HUVECS (B). HUVECs were incubated with fluorescent 
PMPs in the presence of increasing amounts of Gas6 and uptake was monitored by flow cytometry 
(C). TAM-specificity in the uptake was evaluated by incubating the cells with polyclonal antibodies 
against the extracellular domain of the different TAMs before and during uptake (D). Successful 
biotinylation of PMPs was measured by binding of Alexa Fluor488-conjugated streptavidin by flow 
cytometry (E) and by western blot analysis followed by detection with HRP-conjugated biotin-avidin 
complexes (F). Several PMP-proteins were found to be biotinylated, of which the most abundant 
around 100 kDa was used for quantification. Biotinylated PMPs pre-incubated with increasing 
amounts of Gas6 were added to HUVECs cells and after 1h at 37oC cells were analyzed for biotin 
content. A representative biotin detection by western blot is shown to the left (G). Fluorescent PMPs 
were incubated with Gas6 and a double amount of unlabeled PMPs before incubating with HUVECs 
for 1h. The amount of phagocytosed labeled PMPs was measured in a flow cytometer (H). PMPs were 
incubated with Gas6 in the presence or absence of 2.5 mM EDTA before adding to the cells. MP-
ingestion was measured as above (I). Data in bar graphs are shown as mean and SD of three 
individual experiments except for panel E, which includes two separate experiments. Other panels 
show representative data from at least three separate experiments. ns, not significant; ****, p<0.0001.  
 
FIGURE 3. HAECs ingest PMPs in a Gas6-Axl dependent manner. TAM expression was evaluated in 
the HAECs using flow cytometry (A). Relative expression of Axl and Mer at the cell surface was 
evaluated by western blotting of immunoprecipitated TAMs after cell surface biotinylation (B). 
Fluorescent PMPs were incubated with Gas6 and fed to HAECs for 1h at 37oC. PMP phagocytosis 
was measured by flow cytometry (C). The TAM-dependence of the uptake was evaluated by 
introducing TAM-targeting antibodies during the uptake (D) or by treating the HAECs with siRNA 
targeting the different TAMs (E). The knock-down efficiency of the TAM siRNA treatment is shown 
in F. Fluorescent PMPs were incubated with recombinant in-house purified Gas6 or commercially 
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available non-gamma-carboxylated Gas6 before incubation with HAECs (G). Uptake was measured 
as described in panel D. Fluorescent PMPs with or without Gas6 were incubated with HAECs for 
increasing time at 37oC to measure the time-dependency of the uptake (H). Uptake was measured 
using flow cytometry as described in panel E. Data in bar graphs are shown as mean and SD of three 
individual experiments. Other panels show representative data from at least three separate 
experiments.  ns, not significant; **, p<0.01; ***, p<0.001; ****, p<0.0001.   
 
 
FIGURE 4. Protein S blocks basal PMP uptake only in HAECs. Fluorescent PMPs pre-treated with or 
without 10 µg/ml protein S were incubated for 1h with HUVECs (A) or HAECs (B). PMP uptake was 
measured by flow cytometry. The combinatory effect of protein S and Gas6 on PMP-uptake was 
measured by incubating fluorescent PMPs with 10 µg/ml protein S in the presence of increasing 
amounts of Gas6 before incubating the PMPs with HUVECs (C) or HAECs (D). Fluorescent PMPs 
were incubated with 250 ng/ml Gas6 and 0 or 1 ug/ml annexin V before feeding them to HUVECs 
(E). PMPs were incubated with 250 ng/ml Gas6 and increasing amounts of sAxl before uptake was 
evaluated in HAECs (F) and HUVECs (G). Data show the mean and SD of at least three separate 
experiments except for panels A-B, which show representative histograms from three individual 
experiments. ns, not significant; *, p<0.05; **,p<0.001; ****, p<0.0001.  
 
 
FIGURE 5. PMPs are actively ingested and transported to the nuclear surrounding. HAECs were 
grown on cover slips and incubated with fluorescent PMPs in the presence and absence of Gas6 for 
4h. Cells were fixed and the cell membrane was stained with an antibody against CD31, after which 
uptake was evaluated using confocal microscopy. CD31 is shown in red, PMPs in green and the 
nuclei in blue (A). Uptake of Gas6-coated, biotinylated PMPs was investigated using transmission 
electron microscopy. Cells were stained with an avidin-gold conjugate to visualize PMPs. Arrows 
point to PMPs moving freely in the cell and arrowheads to PMPs enclosed in endosome-like 
compartments (B). Scale bars represent 20 µm (A) and 500 nm (B). HAEC cells were treated with 
cytochalasin D or nocodazole prior to and during uptake of fluorescent PMPs in the presence and 
absence of Gas6. Uptake was measured by flow cytometry (C). Successful disruption of the 
microtubule and the actin networks was verified by staining the cells with and anti-β-tubulin and 
fluorescent phalloidin (D).  Data in A show representative images from at least three individual 
experiments, whereas panel C shows the mean and SD of three separate experiments. B shows two 
out of several representative images from one uptake experiment. ****, p<0.0001. 
 
FIGURE 6. PMP-bound Gas6 activates Axl better than free Gas6. HAEC cells were stimulated with 
PMPs alone or PMPs together with Gas6 for 15 min, after which cells were lysed. Axl 
phosphorylation was measured by western blot in samples after immunoprecipitation with Axl-
specific antibodies. Total Axl in immunoprecipitated samples served as loading control (A). The level 
of Akt (B) and Erk (C) phosphorylation upon stimulation with PMPs in the presence or absence of 
Gas6 was measured in cell lysates. Cells were treated with an Axl kinase inhibitor (R428) for 15 min 
prior to and during uptake of fluorescent PMPs. The level of uptake was measured by flow cytometry 
(D). Data show the mean and SD of three separate experiments. ns, not significant; **, p<0.01; ***, 
p<0.001; ****, p<0.0001.  
 
 
FIGURE 7.  PMPs generated with thrombin and collagen are ingested equally well as ionophore-
generated PMPs. The appearance of platelets stimulated with thrombin/collagen was visualized with 
scanning electron microscopy, showing a more typical platelet activation phenotype compared to 
ionophore-stimulated platelets (A) Scale bars denote 5 µm. The size of thrombin/collagen PMPs was 
compared to that of ionophore PMPs by nanotracking analysis and showed a more heterogenous size 
distribution (B). The amount of PS exposure on the different PMPs was measured by evaluating 
lactadherin binding by flow cytometry (C). Binding of protein S (D) and Gas6 (E) to 
thrombin/collagen PMPs was evaluated by flow cytometry. The uptake of fluorescent 
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thrombin/collagen PMPs into HAECs was measured in the presence of Gas6 and protein S using flow 
cytometry (F). Erythrocyte MPs was measured for their ability to bind lactadherin (G), protein S (H) 
and Gas6 (I). The influence of Gas6 and Protein S on the uptake of fluorescent erythrocyte MPs in 
HAECs was measured by flow cytometry (J). Lactadherin (K), protein S (L) and Gas6 (M) binding to 
THP-1 MPs generated by LPS-stimulation was measured using flow cytometry. The ability of Gas6 
and protein S to modulate the uptake of fluorescent THP-1 MPs in HAECs was measured as above 
(N). Data show the mean and SD of at least three separate experiments, except for histograms, which 
are representative for three experiments. ns, not significant; *, p<0.05. 
 
FIGURE 8. Gas6 increases PMP-induced ICAM and E-selectin expression. HAECs were incubated 
with PMPs in the presence or absence of Gas6 for 20h after which their cell-surface expression of 
adhesion molecules was evaluated by flow cytometry. Data show the mean and SD of three separate 
experiments. ns, not significant; *, p<0.05; **, p<0.01; ***, p<0.001 
 
FIGURE 9. Basal levels of circulating PMPs are not altered in Gas6-/- mice compared to Gas6+/+ 
mice. Levels of circulating CD41+PS+ PMPs (A) or PS+ MPs (B) were measured in Gas6-/- (n=13) and 
Gas6+/+ (n=10) mice using flow cytometry. Horizontal bars denote the median. Statistical significance 
of differences between the groups was carried out using a Mann-Whitney test. ns, not significant. 	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